Medical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
This program is supported by Bristol Myers Squibb; Jazz Pharmaceuticals; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Syndax Pharmaceuticals, Inc.
11:00 a.m. - 2:00 p.m. Pacific time
ACCESS PROGRAM HERE
San Diego Convention Center
Ballroom 20CD
On Demand program will be available here December 7, 2024.
Access Program Here
To maximize the clinical outcomes for individual patients, practicing healthcare professionals must have mastered how to leverage the evidence and possess the competence to apply treatment guidelines and the latest emerging data with regard to the many recent approvals in this therapeutic space. To ensure competence and improve patient outcomes, strategic educational programming is necessary. This program will focus on how to best leverage emerging evidence for currently available therapies and proactively manage and mitigate treatment-related toxicities.
Chair:
Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Speakers:
Jessica Altman, MD
Professor of Medicine, Hematology Oncology Division, Northwestern University
Chicago, IL
Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Boston, MA
Gail J. Roboz, MD
Weill Cornell Medicine/New York Presbyterian Hospital
New York, NY
Joshua F. Zeidner, MD
University of North Carolina
Chapel Hill, NC
Kelly McGregor
, MJH Events
Email: kmcgregor@mjhevents.com